This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Theravance, J&J Ink Deal for Inflammatory Intestinal Drug
by Zacks Equity Research
Theravance (TBPH) signs a global collaboration agreement with Johnson & Johnson to jointly develop and commercialize TD-1473 for inflammatory intestinal diseases.
Novartis' Cosentyx Label Expanded to Include Scalp Psoriasis
by Zacks Equity Research
Novartis' (NVS) psoriasis drug, Cosentyx is already approved for the treatment of plaque psoriasis, psoriatic arthritis and ankylosing spondylitis.
Merck (MRK) Beats on Q4 Earnings, Lags Sales, Guides for '18
by Zacks Equity Research
Merck (MRK) beats estimates for earnings but misses the same for sales in Q4. Sales of Keytruda remain strong in the quarter.
Vertex (VRTX) Q4 Earnings Beat on Strong CF Products Sales
by Zacks Equity Research
Vertex Pharma (VRTX) fourth-quarter earnings increase from the year-ago period led by strong sales of CF drugs and lower operating expenses.
Alkermes Submits NDA for Depression Candidate to the FDA
by Zacks Equity Research
Alkermes (ALKS) files a new drug application to the FDA for ALKS 5461's effective use in the adjunctive treatment of major depressive disorder (MDD).
Amgen Gets CHMP Nod to Add ENDEAVOR Data on Kyprolis Label
by Zacks Equity Research
Amgen (AMGN) gains consent from the Committee for Medicinal Products for Human Use to add overall survival data from a phase III study on the label of its cancer drug, Kyprolis.
Drug/Biotech Stocks Q4 Earnings Due on Jan 31: LLY & VRTX
by Zacks Equity Research
Two pharma/biotech giants are scheduled to report earnings on Jan 31. Let's take a look at how the companies are placed ahead of the upcoming releases.
Pfizer (PFE) Stock Falls Despite Q4 Earnings & Sales Beat
by Zacks Equity Research
Pfizer (PFE) beats expectations for both earnings and revenues in Q4 and issues an upbeat guidance for 2018. However, shares decline in pre-market trading.
The Zacks Analyst Blog Highlights: Johnson & Johnson, Illinois Tool Works, Bank of New York Mellon, Ford and Capital One Financial
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, Illinois Tool Works, Bank of New York Mellon, Ford and Capital One Financial
Top Analyst Reports for Johnson & Johnson, Illinois Tool Works & BNY Mellon
by Mark Vickery
Today's Research Daily features new research reports on 14 major stocks, including Johnson & Johnson (JNJ), Illinois Tool Works (ITW) and Bank of New York Mellon (BK).
AbbVie (ABBV) Q4 Earnings Beat, 2018 View Raised, Shares Up
by Zacks Equity Research
AbbVie's (ABBV) Q4 earnings top estimates with revenues marginally beating the same. Sales of the company's lead marketed drug, Humira, also rise year over year.
Will J&J (JNJ) Witness Deceleration in 2018 Sales Growth?
by Zacks Equity Research
J&J (JNJ) has a history of issuing a cautious outlook, especially at the beginning of the year. However, there are several tailwinds, which can coax it to improve the 2018 projection.
Zacks Earnings Trends Highlights: Citigroup, Johnson & Johnson, IBM and General Electric
by Zacks Equity Research
Zacks Earnings Trends Highlights: Citigroup, Johnson & Johnson, IBM and General Electric
Will Pfizer (PFE) Surpass Estimates This Earnings Season?
by Zacks Equity Research
While Pfizer's (PFE) new drugs like Ibrance and Xeljanz are likely to drive sales in Q4, genericization of key drugs and supply shortages in legacy Hospira products will hurt sales.
Pfizer's Rituxan Biosimilar Meets Endpoint in Phase III
by Zacks Equity Research
Pfizer's (PFE) biosimilar version of Roche's blockbuster leukemia drug, Rituxan/Mabthera, meets primary endpoint in phase III comparative trial.
Healthcare ETFs in Focus Post JNJ Q4 Results
by Sweta Killa
Investors should closely watch the movement of the JNJ following Q4 results and keep a close eye on ETFs having double-digit allocation to this diversified drug maker.
Four Things to Know About the Q4 Earnings Season
by Sheraz Mian
There is clear momentum on the revenue side, both in terms of growth as well as more numerous revenue beats.
Four Things to Know About the Q4 Earnings Season
by Sheraz Mian
There is clear momentum on the revenue side, both in terms of growth as well as more numerous revenue beats.
J&J (JNJ) Q4 Earnings Top, Pharma Sales Continue to Improve
by Zacks Equity Research
J&J (JNJ) beat estimates for earnings while missing the same for sales in the fourth-quarter. It issued a mixed outlook for 2018.
J&J (JNJ) Beats on Q4 Earnings, Misses Sales, Shares Up
by Zacks Equity Research
J&J (JNJ) beat estimates for earnings while missed the same for sales in the fourth-quarter. It issued a mixed outlook for 2018.
Earnings Momentum Driving Stocks
by Sheraz Mian
The fact that estimates are going up is a big deal and a major change relative to what has been the norm over the last many years.
3 Stocks Likely to Beat Earnings Estimates This Week
by Ryan McQueeney
Investors are always looking to find companies that are poised to post better-than-expected earnings results and experience strong post-earnings gains. Today, we are giving our readers a very special treat: a free look at three of the strongest stocks likely to beat earnings estimates this week.
Healthcare ETFs to Watch As Q4 Earnings Unfold
by Sweta Killa
With earnings surprises well in the cards, the healthcare sector is expected to witness earnings growth of 3% in the fourth quarter, suggesting some upside for healthcare ETFs.
Wynn Resorts, Imax, Johnson & Johnson, Ford and Starbucks as Zacks Bull and Bear of the Day
by Zacks Equity Research
Wynn Resorts, Imax, Johnson & Johnson, Ford and Starbucks as Zacks Bull and Bear of the Day
Upcoming Consumer Earnings Reports to Watch: JNJ, F, SBUX
by Ryan McQueeney
Fourth-quarter earnings season is finally underway, and investors are already getting excited about the upcoming reports from market-moving tech companies like Netflix (NFLX). Make sure to keep an eye on these companies as they prepare to report during the week of January 22.